Drug Trial Radar · NCT02994927
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
Last checked: Nov 20, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
331
Actual
Start
Mar 15, 2017
Primary completion
Sep 7, 2019
Study completion Nov 1, 2019
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Dec 16, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.
Conditions
- ANCA-Associated Vasculitis
Interventions
AvacopanDrug
Avacopan 30 mg twice daily orally for 52 weeks (364 days): \- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose. Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days): * Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule. * Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day.
PrednisoneDrug
Avacopan-matching placebo twice daily orally for 52 weeks (364 days): \- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose. Oral prednisone tapering regimen over 20 weeks (140 days): * Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule. * Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day.
CyclophosphamideDrug
Orally or intravenously administered
RituximabBiological
Intravenously administered
AzathioprineDrug
Orally administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Achieving Disease Remission at Week 26Time frame: Week 26
- Percentage of Subjects Achieving Sustained Disease Remission at Week 52Time frame: Week 52
Locations
198 sites in 20 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Huntsville, Alabama
Clinical Trial Site
Phoenix, Arizona
Clinical Trial Site
Phoenix, Arizona
Clinical Trial Site
Los Angeles, California
Clinical Trial Site
Santa Monica, California
Clinical Trial Site
Aurora, Colorado
Clinical Trial Site
Washington D.C., District of Columbia
Clinical Trial Site
Daytona Beach, Florida
Clinical Trial Site
Tampa, Florida
Clinical Trial Site
Atlanta, Georgia
Clinical Trial Site
Meridian, Idaho
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Indianapolis, Indiana
Clinical Trial Site
Kansas City, Kansas
Clinical Trial Site
Lexington, Kentucky
Clinical Trial Site
Shreveport, Louisiana
Clinical Trial Site
Baltimore, Maryland
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Ann Arbor, Michigan
Clinical Trial Site
Minneapolis, Minnesota
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
Great Neck, New York
Clinical Trial Site
Mineola, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
Chapel Hill, North Carolina
Clinical Trial Site
Greenville, North Carolina
Clinical Trial Site
Winston-Salem, North Carolina
Clinical Trial Site
Cleveland, Ohio
Clinical Trial Site
Columbus, Ohio
Clinical Trial Site
Duncansville, Pennsylvania
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Pittsburgh, Pennsylvania
Clinical Trial Site
Providence, Rhode Island
Clinical Trial Site
Charleston, South Carolina
Clinical Trial Site
Dallas, Texas
Clinical Trial Site
Houston, Texas
Clinical Trial Site
Salt Lake City, Utah
Showing 40 of 198 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.